Gene therapy studies utilizing LVs containing either an anti-sickling βT87Q-globin or γ-globin transgenes was shown to ameliorate the SCD clinical manifestation either in vivo in SCD mouse models [18,19,20] or in vitro using CD34+ cells from SCD patients [21,22,23,24]. The gene discussed is CD34; the disease is Schnyder corneal dystrophy.